1. Home
  2. REGN vs WBD Comparison

REGN vs WBD Comparison

Compare REGN & WBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • WBD
  • Stock Information
  • Founded
  • REGN 1988
  • WBD 1923
  • Country
  • REGN United States
  • WBD United States
  • Employees
  • REGN N/A
  • WBD N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • WBD Cable & Other Pay Television Services
  • Sector
  • REGN Health Care
  • WBD Telecommunications
  • Exchange
  • REGN Nasdaq
  • WBD Nasdaq
  • Market Cap
  • REGN 59.5B
  • WBD 47.6B
  • IPO Year
  • REGN 1991
  • WBD N/A
  • Fundamental
  • Price
  • REGN $585.48
  • WBD $19.08
  • Analyst Decision
  • REGN Buy
  • WBD Buy
  • Analyst Count
  • REGN 23
  • WBD 21
  • Target Price
  • REGN $794.83
  • WBD $15.31
  • AVG Volume (30 Days)
  • REGN 1.1M
  • WBD 78.3M
  • Earning Date
  • REGN 10-28-2025
  • WBD 11-06-2025
  • Dividend Yield
  • REGN 0.60%
  • WBD N/A
  • EPS Growth
  • REGN 5.03
  • WBD N/A
  • EPS
  • REGN 39.67
  • WBD 0.31
  • Revenue
  • REGN $14,214,200,000.00
  • WBD $38,441,000,000.00
  • Revenue This Year
  • REGN N/A
  • WBD N/A
  • Revenue Next Year
  • REGN $4.74
  • WBD $0.35
  • P/E Ratio
  • REGN $14.76
  • WBD $61.48
  • Revenue Growth
  • REGN 5.38
  • WBD N/A
  • 52 Week Low
  • REGN $476.49
  • WBD $7.25
  • 52 Week High
  • REGN $1,024.36
  • WBD $20.24
  • Technical
  • Relative Strength Index (RSI)
  • REGN 53.18
  • WBD 66.30
  • Support Level
  • REGN $555.00
  • WBD $18.83
  • Resistance Level
  • REGN $618.01
  • WBD $19.61
  • Average True Range (ATR)
  • REGN 17.27
  • WBD 0.77
  • MACD
  • REGN 1.89
  • WBD -0.19
  • Stochastic Oscillator
  • REGN 52.72
  • WBD 56.55

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About WBD Warner Bros. Discovery Inc. Series A

Warner Bros. Discovery was formed in 2022 through the combination of WarnerMedia and Discovery Communications. In 2026, it intends to split its global networks business from its streaming and studios businesses, forming two separate companies. The streaming business includes HBO Max, which is rapidly increasing its international footprint in addition to its major presence in the US. Studios include industry leaders in both film and television, which produce movies and television series that are monetized in multiple ways, including theatrical release, sales to third parties, and feeding into Warner's own platforms. Global networks consist of basic cable networks like CNN, TNT, TBS, Discovery, HGTV, and The Food Network. The Discovery+ streaming service will remain part of global networks.

Share on Social Networks: